Valore202020212022202320242025TTMSpese di vendita, generali e amministrative9.07 M10.75 M13.98 M12.98 M13.78 M17.6 M17.6 MRicerca e sviluppo17.29 M23.26 M42.81 M42.29 M54.37 M60.22 M60.22 MReddito operativo-15.91 M-34.02 M-46.4 M-54.92 M-67.91 M-77.63 M-77.63 MProventi non operativi, Totale-319 K238 K1.06 M4.52 M3.89 M3.5 M3.5 MOneri finanziari, al netto degli interessi capitalizzati———————Proventi non operativi, esclusi gli oneri finanziari-319 K238 K1.06 M4.52 M3.89 M3.5 M3.5 MEntrate/uscite straordinarie———————Utile al lordo delle imposte-16.23 M-33.77 M-45.34 M-50.4 M-64.02 M-74.12 M-134.28 MQuota di utile———————Imposte000000—Interessi di minoranza-6 000-9 000-5 000-8 0001 000-5 000-5 000Altri proventi/oneri al netto delle imposte———————Utile netto al lordo delle attività cessate-16.22 M-33.77 M-45.34 M-50.39 M-64.02 M-74.12 M-74.12 MAttività cessate———————Utile netto-16.22 M-33.77 M-45.34 M-50.39 M-64.02 M-74.12 M-74.12 MRegolazione della diluizione———————Dividendi privilegiati———————Utile netto diluito attribuibile agli azionisti ordinari-16.22 M-33.77 M-45.34 M-50.39 M-64.02 M-74.12 M-74.12 MUtile base per azione (EPS base)——-1.6-0.94-0.86-0.8-0.8Utile diluito per azione (EPS diluito)——-1.6-0.94-0.86-0.8-0.8Numero medio di azioni ordinarie in circolazione——28.42 M53.61 M74.26 M92.99 M366.74 MAzioni diluite in circolazione——28.42 M53.61 M74.26 M92.99 M366.74 MEBITDA-15.34 M-33.55 M-46.17 M-54.33 M-67.21 M-76.96 M-76.96 MEBIT-15.91 M-34.02 M-46.4 M-54.92 M-67.91 M-77.63 M-77.63 MCosto del fatturato———————Altri costi del venduto———————Ammortamento e svalutazione (liquidità)569 K475 K232 K592 K708 K664 K664 K
aTyr Pharma Inc
aTyr Pharma is a public biotherapeutics company that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases.
The company's lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 that downregulates both the innate and adaptive immune responses in inflammatory disease states. aTyr is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung disease, a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. ATYR1923 is currently being investigated in a clinical trial in pulmonary sarcoidosis patients.
The company was founded in 2005 and is headquartered in San Diego, California, and led by CEO Sanjay S. Shukla.